Skip to content
AnalystLens

Exelixis 8-K Report, Corporate Update (Sep 11, 2026)

Reports
Other Events
Filing Date
Filed September 11, 2026
Period End
September 10, 2026
Security
EXEL
In the record · 2016–202610-K1110-Q358-K119

EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’17Jan ’17
  2. Material agreement8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Nov ’25Nov ’25

Summary

Summary of the 8-K filed September 11, 2026. Cited figures are marked; the original filing is the authoritative source.

Exelixis, Inc. filed this Form 8-K to report that on September 10, 2026, the U.S. Food and Drug Administration notified the company that it had extended the review period for its new drug application (NDA) for zanzalintinib, in combination with atezolizumab, for the treatment of patients with metastatic colorectal cancer, by three months.

The extension followed an FDA information request to which Exelixis responded by submitting updated safety and efficacy data, which the FDA has deemed a major amendment. The revised Prescription Drug User Fee Act (PDUFA) action date is now March 3, 2027. The filing does not state the original action date, the specific content of the updated data, or the outcome of the review.

Investors should note that the timeline for a potential approval decision on this indication has been pushed back by three months. The filing is a brief Item 8.01 (Other Events) disclosure signed by Brenda J. Hefti, Senior Vice President and General Counsel, on September 11, 2026.

Key Highlights

  1. FDA extended the review period for the zanzalintinib + atezolizumab NDA in metastatic colorectal cancer by three months, notified September 10, 2026.
  2. The extension was triggered by an FDA information request; Exelixis submitted updated safety and efficacy data, which the FDA deemed a major amendment.
  3. The new Prescription Drug User Fee Act action date is March 3, 2027.
  4. The indication under review is metastatic colorectal cancer, with zanzalintinib used in combination with atezolizumab.
  5. The filing is a limited Item 8.01 (Other Events) disclosure and does not include financial results or other financial metrics.
  6. The company's common stock trades under the symbol EXEL on the Nasdaq Stock Market LLC.

Frequently Asked Questions

  1. Why was the FDA review period for zanzalintinib extended?

    The FDA issued an information request, and in response Exelixis submitted updated safety and efficacy data. The FDA deemed this submission a major amendment, which led to the three-month extension of the review period.

  2. What is the new action date for the zanzalintinib NDA?

    The updated Prescription Drug User Fee Act action date is March 3, 2027.

  3. What indication is the zanzalintinib application seeking?

    The NDA is for zanzalintinib in combination with atezolizumab for the treatment of patients with metastatic colorectal cancer.

  4. Does this filing address the outcome of the FDA review?

    No. The filing reports only the extension of the review period and the revised action date. It does not state a decision on the application.